12th Annual Oligonucleotide Networking Event

Accelerating Innovation through Collaboration

Developed by the community for the community

Tuesday 25 - Wednesday 26 March 2025

AstraZeneca, in partnership with Cytiva, Roche, GSK, Novartis, Johnson and Johnson, BioMax, Ionis, Biogen, STPharm and University of Manchester are pleased to invite you to their 12th oligonucleotide networking event. The title of this year's event is "Accelerating Innovation through Collaboration"

This two-day hybrid meeting is kindly being hosted by AstraZeneca in Macclesfield, UK and online for those who are attending virtually. The meeting is free to attend.

Due to the popularity of the event, and to ensure a wider representation at the meeting, tickets are limited to one in-person ticket per organisation in the first instance. To manage this, please request a place via the waitlist and we will be in touch with a link to register if your application to attend is successful. Please look out for emails from Eventbrite in your InBox/Spam as you will need to use this link to register your ticket.

There are over 500 online tickets available to enable everyone to participate.

The themes covered in the 2025 meeting will include:

Commercialisation and Manufacturing of Oligos
Therapeutic Advances
Manufacturability and Comparability
Data Processing & Digital Advances
Characterisation of Oligos
Manufacture and Characterisation of Stereodefined Oligos
Building Successful Oligo Development through Collaborations

The meeting aims to bring together the community of interested professionals and practitioners in industry and academia to discuss the latest developments in this field, explore knowledge transfer issues and share best practise.

AstraZeneca

What science can do

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide.

Macclesfield is the second largest manufacturing site in the AstraZeneca network and our European Centre for packing. This site is home to 4700 employees, who manufacture, pack and distribute medicines to 117 global markets. Here we have supply chain thinking from clinical to commercial all on one site. Macclesfield is home to our IT function, as well as Pharmaceutical Development and Global Medicines Development facilities.

We are dedicated to transforming the future of healthcare by unlocking the power of what science can do for people, society and the planet.